Italia markets open in 7 hours 15 minutes
  • Dow Jones

    29.225,61
    -458,13 (-1,54%)
     
  • Nasdaq

    10.737,51
    -314,13 (-2,84%)
     
  • Nikkei 225

    26.422,05
    +248,07 (+0,95%)
     
  • EUR/USD

    0,9836
    +0,0016 (+0,17%)
     
  • BTC-EUR

    19.851,92
    -83,37 (-0,42%)
     
  • CMC Crypto 200

    444,40
    -1,58 (-0,35%)
     
  • HANG SENG

    17.165,87
    -85,01 (-0,49%)
     
  • S&P 500

    3.640,47
    -78,57 (-2,11%)
     

Pelorus Equity Group Closes $11.8 Million Debt Financing, Enabling Juva Life to Expand Cannabis Operations, Further Clinical Research

·5 minuto per la lettura
Pelorus Management Group
Pelorus Management Group

NEWPORT BEACH, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Pelorus Equity Group (“Pelorus”), the leading provider of commercial real estate loans for the cannabis sector, announced it has closed an $11.8 million financing with Juva Life Inc. (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution.

The primary purpose of the financing, which closed on June 15, 2022, is to finance the exercise of the tenants purchase option on its recently completed Stockton cultivation facility, as well as provide working capital and R&D funding. The facility was recently completed at a cost of $17 million. Juva also plans to use a portion of the funds to further its clinical research development programs on Juva-019 and Juva-041, novel compounds targeting the treatment of inflammation.

“We’re thrilled to fund Juva to acquire its Stockton, California, facility,” said Pelorus Equity Group CEO and Manager of the Pelorus Fund Dan Leimel. “In addition to  advancing Juva’s research on its two compounds, this compelling transaction will support Juva’s development of products derived from cannabis that offer evidence-based therapeutics for the treatment of many challenging health conditions. As we continue to expand our assets under management, we look forward to continuing to provide leaders in the cannabis ecosystem with flexible capital markets solutions that meet the complex deal structures of large, mid-sized and small operators.”

“I am extremely pleased to close this round of debt financing, especially given the recent distressed capital markets and economic conditions,” said Juva CEO and Founder Doug Chloupek. “I believe it is a testament to the excitement around Juva’s cannabis operations as well as our clinical research initiatives. As our cannabis operations continue to grow and generate revenue, it was imperative that we secure our real estate holdings while advancing our pharmaceutical programs. This financing allows us to accomplish both of these goals, while retaining significant equity in our Stockton real estate asset. Additionally, the financing will also provide us with the capital needed to finish construction on our downtown Redwood City retail store which, upon completion, will create a new revenue stream for Juva.”

Pelorus Equity Group Managing Partner Travis Goad added, “As the cannabis industry expands, we are continuing to see significant demand for commercial real estate funding. Over the course of the last year, we have rolled out numerous innovative lending solutions for complex transactions, and in the year ahead, we will look forward to providing our clients in the cannabis sector with more innovative lending solutions and loan programs that enable them to strategically scale their operations and meet their business goals and objectives.”

The financing is secured by the assets of Juva and its subsidiaries, including the real estate held in Stockton. It also includes the issuance of 2,500,000 warrants, each convertible into one common share of the Company, exercisable at $0.18 CAD per share for a period of three years post loan maturity. The loan bears a variable interest rate of 11.5% plus 1M SOFR (SOFR floor of 1.5%) over the 36-month term of the financing.

To date, Pelorus has completed 68 commercial real estate loan transactions and deployed $429 million to cannabis businesses and real estate owners, comprising  3.25 million square feet in eight states across the U.S. With the ability to approve construction draws to reimburse  borrowers in an average of one-to-three days – and by way of a single agreement that covers the financing of the entire project – the Pelorus Fund helps to stabilize cash flow for clients so they can remain focused on their core business. For more information, visit https://pelorusequitygroup.com/.

About Pelorus Equity Group
Pelorus Equity Group (“Pelorus”), the leading provider of commercial real estate loans to cannabis businesses and owners with cannabis-related real estate, and its Pelorus Fund, a private mortgage real estate investment trust (“mREIT”), are changing the commercial real estate lending landscape in the cannabis sector.

Pelorus Fund offers a range of innovative transactional solutions to address the diverse needs of real estate investors and portfolio managers, and its flexible acquisition and bridge lending programs are the direct result of the firm’s involvement in more than 5,000 transactions of varying size and complexity.

Since 1991, Pelorus’ principals quickly understand an opportunity, structure a logical solution and execute a timely close and have participated in more than $5B of real estate investment transactions using both debt and equity solutions. To date, Pelorus has completed 68 commercial real-estate loan transactions and deployed more than $429 million to cannabis businesses and real estate owners, comprising more than 3,250,000 sq. ft. in eight states across the U.S.

With the ability to fund approved construction draws for reimbursement in an average of one to three days and a single agreement covering the financing of the entire project, the Pelorus Fund helps to stabilize cash flow for its clients, so they are able to remain focused on their core business goals and objectives. For more information, visit https://pelorusequitygroup.com/.

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Pelorus Equity Borrower/Broker Inquires:
info@pelorusequitygroup.com

Pelorus Fund Inquires:
investorrelations@pelorusequitygroup.com

Pelorus Equity Group Media Contact:
Ellen Mellody
ellen@mattio.com
+1-570-209-2947

Juva Life Investor Relations Contact:
+1-833-333-5882 (JUVA)
inquiries@juvalife.com